Targeted Osmotic Lysis (TOL) is a revolutionary treatment for advanced cancer, combining a generic drug (a cardiac glycoside) with a proprietary pulsed electric field device.
There are several other promising cardiac glycosides to use in TOL that might be more selective for different sodium pumps and may be used at a later time, but only digoxin is currently FDA-approved for human use.
Digoxin is used extra-label in animal health.
Digoxin has a narrow therapeutic range and its safety profile is considered acceptable when used within that therapeutic range.
For TOL treatment, digoxin is used in the same dosage as if it were being prescribed for cardiac treatment.
Coaxial Ring electric field device:
Prototype device at left is 8’ long with a 35” diameter. ~600 lbs., sized for human patients.
Prototype device at right is 4’ long with an 18” diameter, shown here treating mice.
Both devices use wall power, generate no heat, require minimal shielding and no floor supports.
Device ensures a nearly uniform low amplitude, low frequency electric field throughout the patient area and a pulse pattern optimized to open sodium channels.
Designed and manufactured by The Phantom Laboratory in Greenwich, NY.
A more detailed description of this case may be found here Source >
The process for TOL patients is still currently being defined, but this is how TOL is currently administered.
Take and fix biopsy, assay for overexpression of sodium channels. If candidate is suitable, image tumor and begin dosing drug orally 6 days pre-treatment.
Place patient in device, no sedation or restraints needed. Treat for 2 hours on the first day and 2 hours on the second day, with a break as needed.
Obtain post treatment metrics including quality of life and disease response. Plan additional courses of treatment as indicated.
None of our human cancer patients have exhibited serious adverse events
Many have seen significant tumor shrinkage